phrma logo

PhRMA

PhRMA Sites

Login

Explore Member-Only Resources

Access exclusive advocacy, policy, and research materials through the member site.

Login now

About

About

Our Agenda

Our Agenda

Policy Issues

We believe that patients should have access to innovative medicines.

Learn More

Innovation Ecosystem

Intellectual Property

Research & Development

Future of Medicine

Government Price Setting

International

Innovation Ecosystem

Patient Access & Affordability

PBMs & Middlemen

Hospitals and 340B

Insurance Coverage

Cost of Medicines

Medicare & Medicaid

Patient Access & Affordability

Resources

Our mission is to conduct effective advocacy for public policies that encourage the discovery of important, new medicines for patients by biopharmaceutical research companies.

Learn More

Resources

Resources

Newsroom

Newsroom

Blog

Blog

America's Medicines

PhRMA Foundation

PhRMA Foundation Logo

Voters for Cures

VotersForCures.org Logo

Working for Cures

workersforcures.org logo

This is Innovation

Innovation.org logo

View More

Search in PhRMA

Find resources, news, and articles related to policy issues and scientific innovation.

What are you looking for?

Most Recent

Policy Paper

Press

Blog

Report

Fact Sheet

Event

Resource

Pages

Leader

Author

Comment

not used title

not used title

It’s a new year, but — unfortunately for patients — problems with the 340B Drug Pricing Program remain. Without action from Congress, large nonprofit hospitals across the country will continue to exploit a program meant to help vulnerable patients get the medicines they need.

It’s well documented that the 340B program is not working for patients. Under the program, participating hospitals buy 340B medicines at discounts so steep (averaging nearly 60%) that some medicines may only cost them a penny. The expectation is that hospitals use the money they save to help vulnerable patients access discounted medicines. But the program lacks any kind of meaningful transparency or accountability standards. As a result, many hospitals are taking advantage of the program — pocketing these savings for themselves instead of using the money to lower cost sharing on medicines for vulnerable patients.

Here’s how abuse of the 340B program is hurting patients:

  • 340B hospitals are driving up costs for patients. Hospitals are charging 500% more for medicines than they paid, on average. But 340B hospitals take this even further. The average cost per prescription is more than 150% higher for patients at 340B hospitals compared to non-340B hospitals. Not only are hospitals marking up these drugs but often they also are not lowering cost sharing for low-income and uninsured patients who may be struggling to afford their cost sharing.

  • Consolidation and health care costs are increasing. Studies have found that 340B creates incentives for provider consolidation, and larger 340B hospitals were responsible for roughly 80% of hospital acquisitions between 2016 and 2022. This consolidation creates powerful, large hospital systems that raise costs for patients while reducing quality of care, as the Federal Trade Commission has warned.

  • Access to care for vulnerable patients is getting worse. A majority (65%) of 340B hospitals are not located in the medically underserved communities they’re expected to serve. And this is no accident. As numerous media investigations and experts have found, 340B hospitals are expanding into more affluent areas to generate higher profits while slashing services or closing facilities in underserved communities. A program designed to make health care more equitable has devolved into one that exacerbates disparities in how vulnerable patients access care.

  • Greater hospital profits equal less charity care. A recent analysis examined operating margins and charity care levels of 340B hospitals, finding that the top performing 340B hospitals collected nearly $10 in profit for every $1 they invested in charity care in 2021. Adding insult to injury, nonprofit hospitals, many of which participate in 340B, receive billions in tax breaks each year ostensibly because they are providing community benefits consistent with their charitable purpose, including financial assistance for low-income patients. But patients are often not receiving this assistance. Abuse of the 340B program raises costs for everyone, including payers like Medicare.

Commonsense reforms are needed to get 340B back on track and working for patients. For starters, Congress should require hospitals to share 340B discounts on medicines with eligible patients. Congress should also strengthen eligibility requirements to ensure participating hospitals are truly supporting underserved communities.

A new year provides lawmakers a new opportunity to fix the program and make sure it’s working for vulnerable patients.

Learn more at PhRMA.org/340B

Nicole Longo

Nicole Longo is Deputy Vice President of public affairs at PhRMA focusing on Medicare, 340B, importation and more. She previously worked for a D.C.-based public affairs firm where she assisted a wide range of clients with communications efforts on everything from trade policy to agriculture policy to health care policy. Outside the office, Nicole can be found trying new restaurants (usually Italian), taking an occasional barre class and cheering on the Cincinnati Bengals.

Nicole Longo

Author Twitter

Author LinkedIn

ICYMI: Hospital consolidation is driving up health care costs

August 27, 2026

It's time to modernize 340B: The case for a rebate model

August 19, 2026

ICYMI: Fox business hosts call 340B a ‘Rotten System’ and ‘Cash Cow’ for hospitals

July 23, 2026

340B’s reality: A booming business for hospitals, pharmacies and corporate giants

June 25, 2026

"New year, same exploitation of the 340B program"

340B

New year, same exploitation of the 340B program

January 25, 2024

"New year, same exploitation of the 340B program"

Stay current on policy making

Sign up for email updates and follow us on social. 

About

Our Agenda

Policy Issues

Resources

Blog

Contact Us

Privacy Policy

Terms of Service

Facebook

Facebook

X

Twitter X

LinkedIn

LinkedIn

Instagram

instagram logo

America's Medicines

PhRMA Foundation

Voters for Cures

Working for Cures

Innovation.org

Please type your email

Success!

You've been added to the list